In general, we concluded that m6A regulators are critical agents in the malignant progression of breast cancer, and the high expression of YTHDF1 may have specific roles in breast cancer prognosis and tumor immunity, as well as participate in ceRNA network regulation, which is anticipated to be a potential target in breast cancer immunotherapy. Here, YTHDF1 is linked to neoplasm.